featured
Effects of Tirzepatide in Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial
Lancet 2021 Jun 25;[EPub Ahead of Print], J Rosenstock, C Wysham, JP Frías, S Kaneko, CJ Lee, L Fernández Landó, H Mao, X Cui, CA Karanikas, VT ThieuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.